Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, gastrointestinal and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG , a world leader in offering medicines to protect health, treat disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

* Known as Gl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
(Date:7/31/2014)... 31, 2014 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... initiated the development of its lead molecule, Anatabine Citrate, ... has selected Quotient Clinical, The Translational Pharmaceutics Company, based ... to run its early development programs. The ... by the end of the third quarter with the ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced,follow-up ... of GVAX immunotherapy,for pancreatic cancer which was ... Center. The trial enrolled 60 patients with,operable ... of their tumor and adjuvant radiation and,chemotherapy. ...
... 2002 , CHICAGO/DARMSTADT, Germany, June 4, 2007 – ... the American Society of,Clinical Oncology (ASCO) annual meeting ... patients with newly diagnosed,glioblastoma – a particularly aggressive ... integrin inhibitor targeting the,tumor and its vasculature. , ...
Cached Medicine Technology:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 2Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 3Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 4Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 5Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:7/31/2014)... 2014 Cosmetic Town has introduced a ... doctors. Doctors will be able to verify their patients ... , which guarantees their authenticity. This will help ... to receive information that has been verified to come ... allows Cosmetic Town to filter out fake patients who ...
(Date:7/31/2014)... United Theological Seminary is pleased to ... Donne and Peter J. Bellini. Both began their teaching ... is a Director of Non-Degree Programs, Mark Abbott, who ... Le Donne, Assistant Professor of New Testament, received a ... Testament, Second Temple Judaism, and Greek courses. His research ...
(Date:7/31/2014)... 2014 Jeremiah’s Tavern ... wood to create a unique atmosphere and highlight ... features reclaimed barn siding on the ... mixed softwoods flowing throughout the interior as flooring. ... sister company New Energy Works Timberframers ...
(Date:7/31/2014)... July 31, 2014 NEWwoodworks, fine woodworking ... expanding their brand presence with a website dedicated to ... years, NEWwoodworks has specialized in handcrafted cabinetry, furniture, ... NEWwoodworks has earned a reputation for taking on the ... on. They commonly craft with reclaimed wood, often using ...
(Date:7/31/2014)... Los Angeles, CA (PRWEB) July 31, 2014 ... connects Southern California’s best Plastic Surgeons to consumers considering ... been recommended by their peers whose goal is to ... The doctors are selected through a validated referral ... area who are the best in their respective fields. ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:Growing Seminary Welcomes New Faculty 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2
... resident Daniel Alford, MD, an associate professor of medicine ... in the General Internal Medicine Department at Boston Medical ... Abuse Prevention and Treatment Division with the Boston Public ... nation to receive the Nyswander-Dole Award. The award was ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) reported today its financial results for ... since June 30, 2007 include:, Clinical:, -- Patient enrollment ... in liver transplant patients; -- Patient enrollment continued ... stem cell transplant patients; study enrollment expanded to ...
... Inc.,(Pink Sheets: HRAL) announced that it has received additional ... International, Inc.,(NYSE: WMT ), to open their ninth ... Wal-Mart Store #3195 located at 1070 Major,Mackenzie Drive in ... #7 Unit Y006A in Markham will both officially open ...
... Revenue and EPS Guidance; Provides Preliminary ... 2008 Guidance ... AM ET, BATON ROUGE, La., Oct 30 Amedisys, Inc.,(Nasdaq: AMED ... reported its financial results for the,third quarter ended September 30, 2007: Three-Month ...
... FREISING-WEIHENSTEPHAN, Germany, October 30 Pieris ... Netherlands) today,announced the commencement of a ... for G-Protein Coupled Receptors (GPCRs) and ... has pioneered Anticalins(R) as next generation ...
... Inc. (NYSE: CRY ),a biomaterials, medical device and ... been named vice president, clinical research,effective October 29, 2007. ... of CryoLife Europa, Ltd., based in the U.K., since ... has held several positions with,the Company including project director ...
Cached Medicine News:Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 2Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 2Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 4Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 5Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 6Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 7Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 8Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 9Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 10Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 11Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 12Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 13Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 14Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 15Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 2Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 3Health News:CryoLife Announces Additions to Management Team 2
... The TheraSeed® Pd-103 implant is a ... and remarkable visibility that makes TheraSeed® treatment ... You can be confident that every TheraSeed® ... management services which is required by clinicians ...
... BrachyStar® Needle is designed to help you ... clinically effective brachytherapy procedure. All needles are ... and polished surfaces for smooth entry and ... and sizes assures an ideal match with ...
... is a combination of innovative design, consistently ... BrachySource I-125 implant an ideal choice for ... that every BrachySource I-125 implant order is ... is required by clinicians who must meet ...
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
Medicine Products: